Alectinib (Alecensa, Roche) is indicated for 'adjuvant treatment for adult patients with Stage IB (tumours ≥4cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) following complete tumour resection'.
The dosage schedule is available in the summary of product characteristics for alectinib.
The list price of 150 mg alectinib is £5,032 per 224‑capsule pack (excluding VAT; BNF online, accessed August 2024). The cost of a course of treatment is £172,068.
The company has a commercial arrangement (simple patient access scheme). This makes alectinib available to the NHS with a discount. The size of the discount is commercial in confidence.